Are zolbetuximab and zolbetuximab the same drug and explanation of naming differences

Zolbetuximab (Zolbetuximab) is a new monoclonal antibody drug that mainly targets CLDN18.2 (claudin 18 isoform 2) and is used for the treatment of gastric cancer and gastroesophageal junction adenocarcinoma. This type of drug specifically recognizes CLDN18.2-expressed tumor cells and activates the immune system to attack cancer cells while reducing damage to normal tissues, thus showing certain anti-tumor efficacy in clinical trials. It is an important breakthrough in the field of targeted treatment of gastric cancer in recent years, providing a new treatment option for patients with positive specific molecular markers.

In terms of drug naming,"Zolbetuximab" is its Chinese trade name or generic name, while "Zolbetuximab" is its international nonproprietary name (International Nonproprietary Name, INN), both of which refer to the exact same drug entity. During the R&D and marketing process, drugs usually have both English and localized Chinese names so that they can be uniformly identified in clinical use, scientific research documents and drug registrations in different countries and regions. This naming strategy is common in transnational drug administration and academic communication and can reduce confusion and ensure safe medication use.

It should be noted that whether the Chinese name"Zolbetuximab" or the English name "Zolbetuximab" is used, the chemical composition, targeting mechanism, indications and dosage regimen of the drug are completely consistent. In clinical practice, doctors and pharmacists usually choose corresponding names for communication based on the region and patient habits, but this will not affect the efficacy and safety of the drug. Therefore, identification of name differences is primarily a linguistic and registration-level difference rather than a pharmacological difference.

In summary,"Zolbetuximab" and "Zolbetuximab" are two different names for the same drug. The Chinese name is more suitable for Chinese literature, clinical prescriptions and patient communication, while the English name is widely used in international academic research, multinational clinical trials and drug registration. Understanding this can help medical staff and patients correctly identify medications and avoid misunderstandings or duplication of medications due to name differences.

Keyword tags:

Zolbetuximab, Zolbetuximab, CLDN18.2, gastric cancer, gastroesophageal junction cancer, drug nomenclature

Reference materials:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8015176/